TORONTO, June 11, 2021 (GLOBE NEWSWIRE) Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of innovative Anti-Cancer Therapy (“ACT”) technologies intended to safely and effectively destroy various cancers, bacteria and viruses, while preserving patient Quality Of Life (“QOL”) announced today the launch of the seventh US-based Clinical Study Site (“CSS”); specifically, the Un
Mysterious News Briefly June 10, 2021 A UFO reported by many people across the state of Arizona was initially said to be a weather balloon but turned out to be a large research balloon launched from NASA’s Columbia Scientific Balloon Facility in Ft. Sumner, New Mexico. A sign of the times – a lot. Read more »
More than 264 million individuals of all ages suffer from depression globally. While there are effective treatments for moderate and severe depression, scientists have been investigating non-traditional therapies as a viable option for the past decades since a significant proportion of people with depression (around 15 percent) don t respond to typical antidepressant medications.
Now, a new study from the University of Chicago Medicine and Washington University has discovered that a low dose of nitrous oxide, often called laughing gas, can ease symptoms of depression that are otherwise resistant to existing drugs.
Nitrous oxide is a common anesthetic used in dentistry and surgery to provide short-term pain relief. The study, published in the journal
E-Mail
A new study at the University of Chicago Medicine and Washington University found that a single inhalation session with 25% nitrous oxide gas was nearly as effective as 50% nitrous oxide at rapidly relieving symptoms of treatment-resistant depression, with fewer adverse side effects. The study, published June 9 in
Science Translational Medicine, also found that the effects lasted much longer than previously suspected, with some participants experiencing improvements for upwards of two weeks.
These results bolster the evidence that non-traditional treatments may be a viable option for patients whose depression is not responsive to typical antidepressant medications. It may also provide a rapidly effective treatment option for patients in crisis.